<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>S Briscoe | Tristan Snowsill</title>
    <link>https://www.tristansnowsill.co.uk/author/s-briscoe/</link>
      <atom:link href="https://www.tristansnowsill.co.uk/author/s-briscoe/index.xml" rel="self" type="application/rss+xml" />
    <description>S Briscoe</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>Â© 2020 Tristan Snowsill</copyright><lastBuildDate>Fri, 01 Dec 2017 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://www.tristansnowsill.co.uk/images/icon_hu050d7ab96a8b87ebb29a3f4b58eca100_52805_512x512_fill_lanczos_center_2.png</url>
      <title>S Briscoe</title>
      <link>https://www.tristansnowsill.co.uk/author/s-briscoe/</link>
    </image>
    
    <item>
      <title>A systematic review of test accuracy studies evaluating molecular micro-satellite instability testing for the detection of individuals with lynch syndrome</title>
      <link>https://www.tristansnowsill.co.uk/publication/coelho-2017-a-systematic-review-of-test-accuracy-studies/</link>
      <pubDate>Fri, 01 Dec 2017 00:00:00 +0000</pubDate>
      <guid>https://www.tristansnowsill.co.uk/publication/coelho-2017-a-systematic-review-of-test-accuracy-studies/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Molecular testing for Lynch syndrome in people with colorectal cancer: Systematic reviews and economic evaluation</title>
      <link>https://www.tristansnowsill.co.uk/publication/snowsill-2017-molecular-testing-for-lynch-syndrome/</link>
      <pubDate>Fri, 01 Sep 2017 00:00:00 +0000</pubDate>
      <guid>https://www.tristansnowsill.co.uk/publication/snowsill-2017-molecular-testing-for-lynch-syndrome/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: A systematic review and economic evaluation</title>
      <link>https://www.tristansnowsill.co.uk/publication/huxley-2017-the-clinical-effectiveness-and-cost-effectiveness-of-cetuximab/</link>
      <pubDate>Sun, 01 Jan 2017 00:00:00 +0000</pubDate>
      <guid>https://www.tristansnowsill.co.uk/publication/huxley-2017-the-clinical-effectiveness-and-cost-effectiveness-of-cetuximab/</guid>
      <description></description>
    </item>
    
    <item>
      <title>COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCER</title>
      <link>https://www.tristansnowsill.co.uk/publication/tikhonova-2016-cost-effectiveness-of-cetuximab-and-panitumumab/</link>
      <pubDate>Sun, 01 May 2016 00:00:00 +0000</pubDate>
      <guid>https://www.tristansnowsill.co.uk/publication/tikhonova-2016-cost-effectiveness-of-cetuximab-and-panitumumab/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): A systematic review and economic model</title>
      <link>https://www.tristansnowsill.co.uk/publication/crathorne-2016-the-effectiveness-and-cost-effectiveness-of-erythropoiesis/</link>
      <pubDate>Mon, 01 Feb 2016 00:00:00 +0000</pubDate>
      <guid>https://www.tristansnowsill.co.uk/publication/crathorne-2016-the-effectiveness-and-cost-effectiveness-of-erythropoiesis/</guid>
      <description></description>
    </item>
    
    <item>
      <title>MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS</title>
      <link>https://www.tristansnowsill.co.uk/publication/snowsill-2014-model-based-cost-utility-analysis-of-erythropoiesis-stimulating-agents/</link>
      <pubDate>Sat, 01 Nov 2014 00:00:00 +0000</pubDate>
      <guid>https://www.tristansnowsill.co.uk/publication/snowsill-2014-model-based-cost-utility-analysis-of-erythropoiesis-stimulating-agents/</guid>
      <description></description>
    </item>
    
    <item>
      <title>1498P WHAT IS THE CLINICAL EFFECTIVENESS OF ERYTHROPOIESIS STIMULATING AGENTS FOR THE TREATMENT OF CANCER TREATMENT-INDUCED ANAEMIA?</title>
      <link>https://www.tristansnowsill.co.uk/publication/crathorne-2014-what-is-the-clinical-effectiveness-of-erythropoiesis/</link>
      <pubDate>Mon, 01 Sep 2014 00:00:00 +0000</pubDate>
      <guid>https://www.tristansnowsill.co.uk/publication/crathorne-2014-what-is-the-clinical-effectiveness-of-erythropoiesis/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A COST-EFFECTIVENESS ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATING CANCER-TREATMENT INDUCED ANAEMIA</title>
      <link>https://www.tristansnowsill.co.uk/publication/huxley-2014-a-cost-effectiveness-analysis-of-erythropoiesis-stimulating/</link>
      <pubDate>Mon, 01 Sep 2014 00:00:00 +0000</pubDate>
      <guid>https://www.tristansnowsill.co.uk/publication/huxley-2014-a-cost-effectiveness-analysis-of-erythropoiesis-stimulating/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
